Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist

(2011) R Parameswaran et al.   LEUKEMIA

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

(2011) E Weisberg et al.   LEUKEMIA

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

(2010) F Fei et al.   LEUKEMIA

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

(2009) J. F. DiPersio et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

The leukemic stem cell niche: current concepts and therapeutic opportunities

(2009) S. W. Lane et al.   BLOOD

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

(2008) A. Agarwal et al.   BLOOD

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

(2008) S Tavor et al.   LEUKEMIA

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

(2008) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

(2008) L. Jin et al.   MOLECULAR CANCER THERAPEUTICS